Scientific and Ethical Advisory Board (SEAB)
The Scientific and Ethical Advisory Board (SEAB) is an external consultative body which is formed to ensure and improve the scientific performance and the quality of results of DECISION. The SEAB advises the General Assembly (GA) and the Project Management Office (PMO) upon request, and provides non-binding advice as decision making support. Members of the SEAB are cordially invited to attend the annual GA meetings in order to monitor the progress within each work packages, assess the scientific quality, and to provide critique and feedback, but do not have a right to vote. The SEAB will also consider and mention any ethical issues which may require stronger attention.
Prof. Dr. Timothy Radstake
Global Development Lead Immunology Clinical Development at AbbVie
Send message
Dr. Clary Clish
Senior Director of the Metabolomics Platform & Scientist at the BROAD Institute
Send message
Dr. Fernando García López
Professor in Bioethics and Law at the University of Barcelona
Send message
Impact Board (IB)
The Impact Board (IB) consists of junior and senior members of DECISION, from academia and industry, as well as patient representatives. The IB is responsible for designing a structured communication plan for dissemination and the exploitation of the project’s results, monitor the steps being taken, and oversee and evaluate the comprehensive internal and external dissemination and societal impact of the project’s results and knowledge gain. In addition, the IB protects DECISION’s intellectual property rights (IPR).
The IB is chaired by Marko Korenjak, current president of ELPA.
Dr. Richard Moreau
Hepatology Consultant at Assistance Publique Hôpitaux de Paris
Phone: +33 157 277 510
Send message